Harding, S A <br/><br/>
Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus.  [electronic resource] 

 -  Heart (British Cardiac Society)  Sep 2006 
 - 1335-7 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-201X 
<br/><br/><label>Standard No.: </label>10.1136/hrt.2005.083006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Chemokine CCL5--metabolism<br/>Clopidogrel<br/>Diabetes Mellitus, Type 2--blood<br/>Humans<br/>Leukocytes, Mononuclear--drug effects<br/>Lymphocyte Activation--drug effects<br/>Middle Aged<br/>Platelet Aggregation--drug effects<br/>Platelet Aggregation Inhibitors--pharmacology<br/>Ticlopidine--analogs & derivatives